Literature DB >> 23064737

PET could predict response to neoadjuvant therapy and long-term survival of patients with esophageal cancer.

Wen-Ping Wang, Kang-Ning Wang, Long-Qi Chen.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23064737     DOI： 10.1007/s00268-012-1825-4

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  5 in total

1.  Accuracy of PET-CT in predicting survival in patients with esophageal cancer.

Authors:  Claire Brown; Ben Howes; Glyn G Jamieson; Dylan Bartholomeusz; Urs Zingg; Thomas R Sullivan; Sarah K Thompson
Journal:  World J Surg       Date:  2012-05       Impact factor: 3.352

2.  Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.

Authors:  Kenneth L Meredith; Jill M Weber; Kiran K Turaga; Erin M Siegel; Jim McLoughlin; Sarah Hoffe; Melis Marcovalerio; Nilay Shah; Scott Kelley; Richard Karl
Journal:  Ann Surg Oncol       Date:  2010-02-06       Impact factor: 5.344

3.  Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

Authors:  Katja Ott; Wolfgang A Weber; Florian Lordick; Karen Becker; Raymonde Busch; Ken Herrmann; Hinrich Wieder; Ulrich Fink; Markus Schwaiger; Jörg-Rüdiger Siewert
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

4.  Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography.

Authors:  B L Brücher; W Weber; M Bauer; U Fink; N Avril; H J Stein; M Werner; F Zimmerman; J R Siewert; M Schwaiger
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

5.  Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.

Authors:  P Flamen; E Van Cutsem; A Lerut; J P Cambier; K Haustermans; G Bormans; P De Leyn; D Van Raemdonck; W De Wever; N Ectors; A Maes; L Mortelmans
Journal:  Ann Oncol       Date:  2002-03       Impact factor: 32.976
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.